Why carry out this study?

• Although ixekizumab has demonstrated significant benefits in clinical and real-world studies for psoriasis (PsO), limited real-world data are available on the effectiveness of ixekizumab from a patient’s perspective shortly (2 to 4 weeks) after the initiation of treatment and upon continuation for 24 weeks.

• This study evaluated the clinical effectiveness, quality of life, sleep, and treatment satisfaction outcomes after initiating ixekizumab based on data collected from the United States (US) Taltz® Customer Support Program (CSP), a comprehensive, no-cost service that offers reimbursement support, injection training, and symptom tracking to assist patients throughout their treatment journey.

What was learned from this study?

• Patient-reported improvements in BSA involvement, itch, skin pain, overall PsO severity, dermatology-specific health-related quality of life, and treatment satisfaction were seen as early as 2 weeks after initiation and continued through week 24. Patient-reported BSA involvement findings from this study were consistent with those reported by physicians in other real-world studies.

• Together these findings demonstrate the benefit of ixekizumab and the benefit of using a CSP for evaluating treatment benefit for patients with a confirmed diagnosis of PsO at initiation and over time.